Hruban R H, van Mansfeld A D, Offerhaus G J, van Weering D H, Allison D C, Goodman S N, Kensler T W, Bose K K, Cameron J L, Bos J L
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Am J Pathol. 1993 Aug;143(2):545-54.
We examined 82 surgically resected or biopsied, formalin-fixed, paraffin-embedded primary adenocarcinomas of the pancreas for the presence of activating point mutations in codon 12 of the K-ras oncogene. Mutations were detected using primer-mediated, mutant-enriched, polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. This combination of mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis and allele-specific oligonucleotide hybridization results in a rapid and sensitive characterization of the mutations in codon 12 of K-ras. Sixty-eight (83%) of the 82 carcinomas examined harbored a point mutation. Of the 68 mutations, 33 (49%) were guanine to adenine transitions, 27 (39%) were guanine to thymine transversions, and eight (12%) were guanine to cytosine transversions. Mutations were found in carcinomas of the head (61 of 75, 81%) as well as in carcinomas of the body or tail (seven of seven, 100%) of the pancreas. The overall prevalence of K-ras point mutations in adenocarcinomas of the pancreas obtained from patients who smoked cigarettes at some point during their lives (88%; 86% in current smokers and 89% in ex-smokers) was greater than that seen in pancreatic adenocarcinomas from patients who never smoked cigarettes (68%, P = 0.046). The presence of K-ras point mutations did not correlate with tumor ploidy, tumor proliferating index, or patient survival. These results demonstrate that primer-mediated, mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis combined with allele-specific oligonucleotide hybridization can be used to detect and characterize mutations in codon 12 of the K-ras oncogene in formalin-fixed, paraffin-embedded tissues, and the results confirm that activating point mutations in codon 12 of the K-ras oncogene occur frequently in adenocarcinomas of the pancreas.
我们检测了82例手术切除或活检的、经福尔马林固定、石蜡包埋的胰腺原发性腺癌,以确定K-ras癌基因第12密码子是否存在激活点突变。使用引物介导的、富含突变体的聚合酶链反应-限制性片段长度多态性分析来检测突变,并通过等位基因特异性寡核苷酸杂交进一步表征。这种富含突变体的聚合酶链反应-限制性片段长度多态性分析与等位基因特异性寡核苷酸杂交相结合的方法,能够快速且灵敏地表征K-ras第12密码子的突变。在检测的82例癌中,有68例(83%)存在点突变。在这68个突变中,33个(49%)是鸟嘌呤到腺嘌呤的转换,27个(39%)是鸟嘌呤到胸腺嘧啶的颠换,8个(12%)是鸟嘌呤到胞嘧啶的颠换。在胰腺头部的癌(75例中的61例,81%)以及胰腺体部或尾部的癌(7例中的7例,100%)中均发现了突变。在一生中曾有过吸烟史的患者所患胰腺腺癌中,K-ras点突变的总体发生率(88%;当前吸烟者中为86%,既往吸烟者中为89%)高于从未吸烟患者的胰腺腺癌(68%,P = 0.046)。K-ras点突变的存在与肿瘤倍体、肿瘤增殖指数或患者生存率无关。这些结果表明,引物介导的、富含突变体的聚合酶链反应-限制性片段长度多态性分析与等位基因特异性寡核苷酸杂交相结合,可用于检测和表征福尔马林固定、石蜡包埋组织中K-ras癌基因第12密码子的突变,并且结果证实K-ras癌基因第12密码子的激活点突变在胰腺腺癌中频繁发生。